Johnson & Johnson Launches Next Satellite Center for Global Health Discovery at Holistic Drug Discovery and Development Centre, University of Cape Town, Focused on Antimicrobial Resistance (AMR)
Cape Town, South Africa, April 25, 2022 – Johnson & Johnson (the Company) today announced the launch of the J&J Satellite Center for Global Health Discovery (Satellite Center) at the Holistic Drug Discovery and Development (H3D) Centre, University of Cape Town, in Cape Town, South Africa. This marks the latest expansion of the J&J Centers for Global Health Discovery (J&J Centers), a global network of research collaborations between the Company and leading research institutions to accelerate translational and discovery research to address some of the world’s most pressing global health challenges. The Sa...
Source: Johnson and Johnson - April 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth in the first quarter of 2022
Basel, 25 April 2022Group sales increase 11%1 at constant exchange rates (CER) and 10% in Swiss francsPharmaceuticals Divisionsales up 6%; continued strong sales of new medicines for severe diseases. Impact of biosimilars decreases as expected.Diagnostics Divisionsales grow 24% due to good momentum in base business and continued high demand for COVID-19 tests. After a strong first quarter, significant decline in COVID-19-related testing expected.Highlights in the first quarter:FDA approval of Vabysmo (severe eye diseases); CHMP recommends EU approval of Polivy combination (aggressive form of blood cancer), Tecentriq (early...
Source: Roche Media News - April 25, 2022 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth in the first quarter of 2022
Group sales increase 11%1 at constant exchange rates (CER) and 10% in Swiss francsPharmaceuticals Divisionsales up 6%; continued strong sales of new medicines for severe diseases. Impact of biosimilars decreases as expected.Diagnostics Divisionsales grow 24% due to good momentum in base business and continued high demand for COVID-19 tests. After a strong first quarter, significant decline in COVID-19-related testing expected.Highlights in the first quarter:FDA approval of Vabysmo (severe eye diseases); CHMP recommends EU approval of Polivy combination (aggressive form of blood cancer), Tecentriq (early-stage non-small cel...
Source: Roche Investor Update - April 25, 2022 Category: Pharmaceuticals Source Type: news

The Connection Between IBD and Aging
Inflammatory bowel disease (IBD) has long been thought of as an ailment of middle, or even young, adulthood. The chronic illness—which includes Crohn’s disease and ulcerative colitis, and can cause abdominal pain, diarrhea, bleeding, and decreased quality of life—impacts about 3.1 million people in the U.S. However, it is far from a disease only of the young and middle-aged. More than a quarter of people with IBD are elderly, a figure that is projected to climb to 30% by 2030, according to a 2021 Gastroenterology & Hepatology article. Even more underappreciated is the growing population of people who ...
Source: TIME: Health - April 8, 2022 Category: Consumer Health News Authors: Katherine Harmon Courage Tags: Uncategorized Disease healthscienceclimate Source Type: news

Janssen Announces Health Canada Approval of RYBREVANT ® (amivantamab), the First and Only Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Toronto, ON, April 4, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) approving RYBREVANT® (amivantamab), a fully-human, bispecific antibody, for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.[i] Health Canada NOC/c is granted to promising new therapies for patients diagnosed with serious, life-threate...
Source: Johnson and Johnson - April 4, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

U.S. FDA grants priority review to Roche ’s Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults
If approved,Actemra/RoActemra would be the first U.S. FDA-approvedimmunomodulator for the treatment of COVID-19 inhospitalised patientsSince the beginning of the pandemic, more than one million peoplehospitalised with COVID-19 have been treated withActemra/RoActemra worldwide1Actemra/RoActemra is approved for the treatment of COVID-19 in many territories including the European UnionRoche has established a comprehensive access approach to improve availability ofActemra/RoActemra around the worldBasel, 04 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has acce...
Source: Roche Investor Update - April 4, 2022 Category: Pharmaceuticals Source Type: news

U.S. FDA grants priority review to Roche ’s Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults
If approved,Actemra/RoActemra would be the first U.S. FDA-approvedimmunomodulator for the treatment of COVID-19 inhospitalised patientsSince the beginning of the pandemic, more than one million peoplehospitalised with COVID-19 have been treated withActemra/RoActemra worldwide1Actemra/RoActemra is approved for the treatment of COVID-19 in many territories including the European UnionRoche has established a comprehensive access approach to improve availability ofActemra/RoActemra around the worldBasel, 04 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has acce...
Source: Roche Media News - April 4, 2022 Category: Pharmaceuticals Source Type: news

CT shows long-term lung damage after COVID-19
More than half of people who contract COVID-19 pneumonia show evidence on ches...Read more on AuntMinnie.comRelated Reading: Study: Divers should undergo chest CT three months after COVID-19 Less cancer screening due to COVID may mean higher death rates SARS-CoV-2 infection may lead to small-airways disease ISCT webinar outlines how to differentiate EVALI from COVID-19 Breakthrough COVID-19 infection milder in vaccinated patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 30, 2022 Category: Radiology Source Type: news

New, Simpler Pneumococcal Vaccine Recommendations for 2022 New, Simpler Pneumococcal Vaccine Recommendations for 2022
Dr Sandra Fryhofer breaks down the latest guidelines for pneumococcal vaccination among adults.Medscape Internal Medicine (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - March 28, 2022 Category: Intensive Care Tags: Internal Medicine Commentary Source Type: news

It ’ s Time to Rethink Your COVID-19 Risk Tolerance
The U.S. is taking a crash course in learning to “live with the virus.” Policymakers and health experts agree that we have migrated to a less-disruptive COVID-19 endemic phase. This has produced extensive commentary on what living with the virus, and achieving the “new normal” might look like—liberating some while confusing others. Many people have spent two years avoiding and fearing the virus and are now being advised that it’s safe to unmask and to resume a normal social life. For them, this has not ushered in a comfortable sense of natural transition, but instead has caused a nationa...
Source: TIME: Health - March 22, 2022 Category: Consumer Health News Authors: Steven Phillips Tags: Uncategorized COVID-19 Source Type: news

It ’s Time to Rethink Your COVID-19 Risk Tolerance
The U.S. is taking a crash course in learning to “live with the virus.” Policymakers and health experts agree that we have migrated to a less-disruptive COVID-19 endemic phase. This has produced extensive commentary on what living with the virus, and achieving the “new normal” might look like—liberating some while confusing others. Many people have spent two years avoiding and fearing the virus and are now being advised that it’s safe to unmask and to resume a normal social life. For them, this has not ushered in a comfortable sense of natural transition, but instead has caused a nationa...
Source: TIME: Health - March 22, 2022 Category: Consumer Health News Authors: Steven Phillips Tags: Uncategorized COVID-19 Source Type: news

Staffing Shortages Are Top Patient Safety Concern: Report Staffing Shortages Are Top Patient Safety Concern: Report
Also on the top 10 list are healthcare workers ' mental health, vaccine errors, non-ventilator-associated pneumonia, emergency use authorization, and telemetry monitoring.Medscape Medical News (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - March 14, 2022 Category: Emergency Medicine Tags: Family Medicine/Primary Care News Source Type: news

U.S. FDA Approves CARVYKTI ™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., February 28, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.1 The approval is based on data from the pivotal CARTITUDE-1 study, which included patients who had received a median of six prior treatment regimens (range, 3-18), and had previously rec...
Source: Johnson and Johnson - March 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

COVID-19 Killed My Grandfather. But My Dad Was Too Busy Treating COVID-19 Patients to Grieve Him
In early February, I got the call I’d dreaded for months: my 82-year-old grandfather, Charlie Law, had died. I’d tried to prepare myself as best as I could; Grandpa had Parkinson’s disease and dementia, and he had been in physical and mental decline for about four years. Still, I hadn’t seen my grandparents in person for two of those years because of the pandemic. Once the initial waves of shock and sadness had washed over me, I was surprised to find I was angry. Losing my grandfather was inevitable, but it felt as if the disease that finally took his life—COVID-19—was not. Although my g...
Source: TIME: Health - February 24, 2022 Category: Consumer Health News Authors: Tara Law Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

5 Things to Know About New Pneumococcal Vaccine Guidance 5 Things to Know About New Pneumococcal Vaccine Guidance
Adult pneumococcal vaccine recommendations have been considered some of the most complicated vaccine recommendations to appropriately implement. The good news: Implementation just got simpler.CDC Expert Commentary (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 17, 2022 Category: Allergy & Immunology Tags: Infectious Diseases Commentary Source Type: news